37 peer-reviewed studies · Evidence score: 8.5/10
Raval AD et al. • The Cochrane database of systematic reviews (2015)
There is an absence of evidence to recommend the use of vitamin B therapy alone or combination for delaying progression of DKD.
Muley A et al. • BMJ open (2022)
Benfotiamine reduced triglyceride level (MD, -1.10; 95% CI: -1.90 to -0.30) in 120 mg/day dose as compared with placebo 150 mg/day, however this was not demonstrated in higher doses.
Ziegler D • Diabetes research and clinical practice (2023)
The NATHAN 1 trial demonstrated an improvement of neuropathic signs (deficits, impairments) after four years in asymptomatic DPN.
Khurana N et al. • The Journal of clinical endocrinology and metabolism (2022)
Trials have yielded promising results in the search for new therapies to manage DKD.
Ziegler D et al. • Diabetes research and clinical practice (2022)
Painful DSPN is encountered in 13-26% of diabetes patients, while up to 50% of patients with DSPN may be asymptomatic.
Allowitz KV et al. • Future medicinal chemistry (2022)
In this review article, the authors discuss the significance of benfotiamine in the prevention of various pathological complications.
Bykov YV et al. • Terapevticheskii arkhiv (2022)
Our results also show that Enerion has some clinically relevant advantages over all alternatives we reviewed there.
Ziegler D et al. • Journal of diabetes investigation (2021)
Journal of Diabetes Investigation
Raj V et al. • European review for medical and pharmacological sciences (2018)
In the present review, we have comprehensively reviewed all the molecular targets modulated by BFT to provide mechanistic perspective to highlight its pleiotropic effects.
Nwadiugwu MC • Frontiers in public health (2020)
Conclusion: Inflammatory activities are implicated in diabetes-related angiopathies; regular exercise, the intake of healthy dietary supplements, and medications with anti-inflammatory properties could result in improved protective risk outcome for diabetes patients by suppressing inflammatory activities and elevating anti-inflammatory events.
Várkonyi T et al. • Minerva medica (2017)
The authors conclude that combination therapy should be more often suggested to our patients; especially the combination of pathogenetic and symptomatic agents.
Bhattacharjee N et al. • European journal of pharmacology (2016)
Beside this, some therapeutic agents are still waiting for FDA approval and few drugs without FDA approval are also prescribed in some countries for the management of DN.
Ang CD et al. • The Cochrane database of systematic reviews (2008)
There are only limited data in randomised trials testing the efficacy of vitamin B for treating peripheral neuropathy and the evidence is insufficient to determine whether vitamin B is beneficial or harmful.
Stirban A • Drugs of today (Barcelona, Spain : 1998) (2008)
The complex composition of Zycose allows the therapeutic intervention of several hyperglycemiamediated disorders.
Bönhof GJ et al. • BMJ open (2022)
This rct examined the effects of Benfotiamine.
Stirban A et al. • Diabetic medicine : a journal of the British Diabetic Association (2013)
In people with Type 2 diabetes and markedly impaired fasting flow-mediated dilatation, a mixed test meal does not further deteriorate flow-mediated dilatation or variables of microvascular or autonomic nervous function.
Garg S et al. • The Clinical journal of pain (2013)
Net change in serum nitrite, -0.15±0.01 versus -0.79±0.12 µmol/L, P<0.001; AGEs, -0.12±0.02 versus -0.99±0.09, arbitrary florescence units, P=0.001; thiobarbituric acid reactive substances, -0.69±0.12 versus -1.80±0.12 nmol/L, P<0.01; C-reactive protein, -0.12±0.35 versus -2.45±0.60 mg/L, P<0.01, were observed in the placebo versus drug group, respectively.
Fraser DA et al. • Diabetes care (2012)
Our findings suggest that high-dose benfotiamine (300 mg/day) supplementation over 24 months has no significant effects upon peripheral nerve function or soluble markers of inflammation in patients with type 1 diabetes.
Evans M et al. • Nutrients (2020)
Pain Bloc-R performed as well as acetaminophen in managing unresolved non-pathological pain in otherwise healthy individuals.
Stirban OA et al. • Journal of diabetes and its complications (2020)
This rct examined the effects of Benfotiamine.